Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).
- Conditions
- Adult Attention Deficit Disorder
- Interventions
- Device: Transcranial Direct Current Stimulation
- Registration Number
- NCT02206516
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
This study aims at combining imaging techniques and clinical evaluations to assess clinical change as well as brain changes that occur as a result of brain stimulation in adult attention deficit disorder.
- Detailed Description
This study will use clinical measures and cognitive tasks covering 3 different functional domains during functional magnetic resonance imaging (fMRI), ElectroEncephaloGram (EEG) and Ultrasound tagged near infrared spectroscopy (UT-NIRS), to assess functional brain changes as a result of a treatment protocol with Transcaranial direct current stimulation (tDCS) in adults suffering from attention deficit disorder (ADD).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
- Patients between the ages of 18-65(male and female)
- Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV
- Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments.
- Gave informed consent for participation in the study
- If referred by the treating psychiatrist, he or she approves of the subjects participation in the study
- Suffering from other diagnosis on axis 1
- History of drug or alcohol abuse during the last year
- Inability to achieve satisfying level of communication with the subject
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description patients Transcranial Direct Current Stimulation Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
- Primary Outcome Measures
Name Time Method Efficacy will be examined by the change in the CAARS questionnaire from the baseline visit to the determination visit in the treatment group compared to the control group. 6 weeks
- Secondary Outcome Measures
Name Time Method changes in functional activity after 4 weeks of tDCS treatment during response inhibition 6 weeks ROI analysis of right Inferior frontal cortex will be measured during response inhibition in the Go/Nogo task at the end of the 4 weeks of treatment and will be compared to baseline measures.
Trial Locations
- Locations (1)
TASMC
🇮🇱Tel Aviv, Israel